NAV

Fentanyl

Identification

Summary

Fentanylis an opioid analgesic used in anesthesia, for breakthrough cancer pain, or round the clock pain management.

品牌名称
Abstral, Actiq, Duragesic, Effentora, Fentora, Instanyl, Lazanda, Sublimaze, Subsys
Generic Name
Fentanyl
DrugBank Accession Number
DB00813
Background

Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia.8由于这些特点,芬太尼是通讯only used to treat chronic cancer pain or in anesthesia.Label,15,16,17,18,19,20,21Fentanyl is related to other opioids likemorphineandoxycodone.

Fentanyl's high potency has also made it a common adulterant in illicit drugs, especially heroin.8In 2017, 47600 overdose deaths in the United States involved some opioid (over 2/3 of all overdose deaths).22Opioid overdoses kill an average of 11 Canadians daily.23

Fentanyl was FDA approved in 1968.Label,15,16,17,18,19,20,21

Type
Small Molecule
Groups
Approved, Illicit, Investigational, Vet approved
Structure
 3D
Similar Structures
Weight
Average: 336.4705
Monoisotopic: 336.220163528
Chemical Formula
C22H28N2O
Synonyms
  • 1-Phenethyl-4-(N-phenylpropionamido)piperidine
  • 1-phenethyl-4-N-propionylanilinopiperidine
  • Fentanil
  • Fentanila
  • Fentanilo
  • Fentanyl
  • Fentanyl CII
  • Fentanylum
  • N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
  • N-(1-phenethyl-4-piperidyl)propionanilide
  • N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
  • N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
  • N-phenethyl-4-(N-propionylanilino)piperidine
  • N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
  • Phentanyl
External IDs
  • AD 923
  • AD-923
  • IDS-NF-001
  • McN-JR 4263-49
  • R 4263
  • R 5240

Pharmacology

Indication

Fentanyl intravenous or intramuscular injections are indicated for short term analgesia during induction, maintenance, and recovery from general or regional anesthesia.LabelThese injections are also used with a neuroleptic for premedication, induction, and as an adjunct to maintenance of anesthesia.LabelFinally, fentanyl intravenous or intramuscular injections are used with oxygen for anesthesia in high risk patients.Label

Fentanyl sublingual tablets, transmucosal lozenges, buccal tablets, sublingual sprays, transdermal systems, and nasal sprays are indicated for the management of breakthrough pain in opioid tolerant cancer patients who require around the clock pain management.15,16,17,18,19,20

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Fentanyl produces strong analgesia through its activation of opioid receptors.Label,6It has a duration of action of several hours and a wider therapeutic index as patients develop tolerance to opioids.LabelFentanyl is associated with a risk of addiction and abuse and should not be mixed with alcohol or benzodiazepines.Label,15,16,17,18,19,20,21

Mechanism of action

Fentanyl binds to opioid receptors, especially the mu opioid receptor, which are coupled to G-proteins.6Activation of opioid receptors causes GTP to be exchanged for GDP on the G-proteins which in turn down regulates adenylate cyclase, reducing concentrations of cAMP.6Reduced cAMP decreases cAMP dependant influx of calcium ions into the cell.6The exchange of GTP for GDP results in hyperpolarization of the cell and inhibition of nerve activity.6

Target Actions Organism
AMu-type opioid receptor
agonist
 Humans
ADelta-type opioid receptor
agonist
 Humans
UKappa-type opioid receptor
agonist
 Humans
UP-glycoprotein 1 Not Available Humans
Absorption

Fentanyl sublingual tablets are 54% bioavailable15, transmucosal lozenges are 50% bioavailable16, buccal tablets are 65% bioavailable17, sublingual spray is 76% bioavailable18, and nasal spray is 20% more bioavailable than transmucosal20(or approximately 64% bioavailable).

Fentanyl transmucosal lozenges reach a Cmaxof 0.4±0.1ng/mL for a 200µg dose and 2.5±0.6ng/mL for a 1600µg dose with a Tmaxof 20-40 minutes.11The AUC was 172±96ng*min/mL for a 200µg dose and 1508±1360ng*min/mL for a 1600µg dose.11

Fentanyl sublingual spray reached a Cmax0.20±0.06 ng / mL的100µg dose and 1.61±0.60ng/mL for an 800µg dose with a Tmaxof 0.69-1.25 hours, decreasing as the dose increased.12The AUC was 1.25±0.67ng*h/mL for a 100µg dose and 10.38±3.70ng*h/mL for a 800µg dose.12

Fentanyl transdermal systems reached a Cmaxof 0.24±0.20ng/mL with a Tmaxof 3.6±1.3h for a 25µg/h dose.13The AUC was 0.42±0.35ng/mL*h.13

Fentanyl nasal spray reaches a Cmaxof 815±301pg/mL with a Tmaxof less than 1 hour for a 200µg/100µL dose.14The AUC was 3772pg*h/mL.14

Volume of distribution

The intravenous volume of distribution is 4L/kg (3-8L/kg)Label,19. The oral volume of distribution is 25.4L/kg.17In hepatically impaired patients, the intravenous volume of distribution ranges from 0.8-8L/kg.19

Fentanyl crosses the blood brain barrier9and the placenta.10

Protein binding

Fentanyl is 80-85% bound to plasma proteins.15,16,17,18,20In one study, a 0.1µg/L solution of fentanyl was 77.9±1.1% bound to human serum albumin and 12.0±5.4% bound to α-1 acid glycoprotein.7A 0.1µg/L solution of norfentanyl, the primary metabolite of fentanyl, was 7.62±1.2% bound to human serum albumin and 7.24±1.9% bound to α-1 acid glycoprotein.7

Metabolism

Fentanyl is metabolized to a number of inactive metabolites.5Fentanyl is 99% N-dealkylated to norfentanyl by cytochrome P450.5It can also be amide hydrolyzed to despropionylfentanyl, or alkyl hydroxylated to hydroxyfentanyl which is N-dealkylated to hydroxynorfentanyl.5

Hover over products below to view reaction partners

Route of elimination

Within 72 hours, 75% of a dose of fentanyl is excreted in the urine with <7% unchanged, and 9% is excreted in the feces with <1% unchanged.Label,15,19

Half-life

The half life of fentanyl is 7 hours.16The half life of fentanyl sublingual spray is 5-12 hours.18

Clearance

Total plasma clearance of fentanyl is 0.5L/hr/kg (0.3-0.7L/hr/kg)16or 42L/hr.17,20Following an intravenous dose, surgical patients displayed a clearance of 27-75L/h, hepatically impaired patients displayed a clearance of 3-80L/h, and renally impaired patients displayed a clearance of 30-78L/h.19

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Fentanyl has an intravenous LD50of 2.91mg/kg in rats1, an oral LD50of 18mg/kg in rats and 368mg/kg in mice.MSDSThe LD50 in humans is not known.

Symptoms of overdose include respiratory depression, somnolence, stupor, coma, skeletal muscle flaccidity, cold and clammy skin, pupillary constriction, pulmonary edema, bradycardia, hypotension, airway obstruction, atypical snoring, and death.Label,15,16,17,18,19,20In case of overdose, patients should receive naloxone or nalmefene to reverse the action of the opioids as well as supportive measures to maintain the airway or advanced life support in the case of cardiac arrest.Label,15,16,17,18,19,20

Pathways
Pathway Category
Fentanyl Action Pathway Drug action
Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Interacting Gene/Enzyme Allele name Genotype(s) Defining Change(s) Type(s) Description Details
Cytochrome P450 3A4 CYP3A4*20 Not Available 1461_1462insA ADRInferred Poor drug metabolizer, increased adverse drug effects, risk of potentially fatal respiratory depression. Details
Cytochrome P450 3A4 CYP3A4*26 Not Available 802C>T ADRInferred Poor drug metabolizer, increased adverse drug effects, risk of potentially fatal respiratory depression. Details

Interactions

Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction
Integrate drug-drug
interactions in your software
1,2-Benzodiazepine The risk or severity of adverse effects can be increased when Fentanyl is combined with 1,2-Benzodiazepine.
Abacavir Fentanyl may decrease the excretion rate of Abacavir which could result in a higher serum level.
Abametapir The serum concentration of Fentanyl can be increased when it is combined with Abametapir.
Abatacept The metabolism of Fentanyl can be increased when combined with Abatacept.
Acebutolol Fentanyl may decrease the antihypertensive activities of Acebutolol.
Aceclofenac The risk or severity of hypertension can be increased when Fentanyl is combined with Aceclofenac.
Acemetacin The risk or severity of hypertension can be increased when Fentanyl is combined with Acemetacin.
Acenocoumarol The risk or severity of adverse effects can be increased when Fentanyl is combined with Acenocoumarol.
18beplay下载 Acetaminophen may decrease the excretion rate of Fentanyl which could result in a higher serum level.
Acetazolamide The risk or severity of adverse effects can be increased when Fentanyl is combined with Acetazolamide.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
  • Avoid alcohol.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
Ingredient UNII CAS InChI Key
Fentanyl citrate MUN5LYG46H 990-73-8 IVLVTNPOHDFFCJ-UHFFFAOYSA-N
Fentanyl hydrochloride 59H156XY46 1443-54-5 LHCBOXPPRUIAQT-UHFFFAOYSA-N
Product Images
International/Other Brands
Durogesic (Janssen)/Fentanest (Pfizer)/Nasalfent (Archimedes)/Rapinyl (Gedeon Richter)
Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image
Abstral Tablet 100 ug/1 Sublingual Prostrakan Pharmaceuticals 2011-01-07 Not applicable US flag
Abstral Tablet 400 ug/1 Sublingual Galena Biopharma, Inc. 2013-08-08 Not applicable US flag
Abstral Tablet 800 ug/1 Sublingual Prostrakan Pharmaceuticals 2011-01-07 Not applicable US flag
Abstral Tablet 100 ug/1 Sublingual Galena Biopharma, Inc. 2013-08-08 Not applicable US flag
Abstral Tablet 600 mcg Sublingual Paladin Labs Inc. 2011-06-14 2018-06-29 Canada flag
Abstral Tablet 300 ug/1 Sublingual Prostrakan Pharmaceuticals 2011-01-07 Not applicable US flag
Abstral Tablet 200 mcg Sublingual Paladin Labs Inc. 2011-04-18 2018-06-29 Canada flag
Abstral Tablet 800 ug/1 Sublingual Galena Biopharma, Inc. 2013-08-08 Not applicable US flag
Abstral Tablet 300 ug/1 Sublingual Galena Biopharma, Inc. 2013-08-08 Not applicable US flag
Abstral Tablet 600 ug/1 Sublingual Prostrakan Pharmaceuticals 2011-01-07 Not applicable US flag
Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image
Apo-fentanyl Matrix Patch 100 mcg / hour Transdermal Apotex Corporation 2009-05-13 2018-07-12 Canada flag
Apo-fentanyl Matrix Patch 75 mcg / hour Transdermal Apotex Corporation 2009-05-13 2018-07-12 Canada flag
Apo-fentanyl Matrix Patch 50微克/小时 Transdermal Apotex Corporation 2009-05-13 2018-02-20 Canada flag
Apo-fentanyl Matrix Patch 12 mcg / hour Transdermal Apotex Corporation Not applicable Not applicable Canada flag
Apo-fentanyl Matrix Patch 25 mcg / hour Transdermal Apotex Corporation 2009-05-13 2018-07-12 Canada flag
Fentanyl Patch, extended release 50 ug/1h Transdermal bryant ranch prepack 2018-01-10 Not applicable US flag
Fentanyl Patch, extended release 25 ug/1h Transdermal bryant ranch prepack 2007-09-01 2015-02-28 US flag
Fentanyl Patch 25 ug/1h Transdermal 质量护理产品,LLC 2005-01-31 Not applicable US flag
Fentanyl Patch, extended release 50 ug/1h Transdermal Directrx 2015-01-01 Not applicable US flag
Fentanyl Patch 25 ug/1h Transdermal Mylan Pharmaceuticals Inc. 2005-01-31 Not applicable US flag
Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image
Innovar Inj Fentanyl citrate(.05 mg / mL)+Droperidol(2.5 mg / mL) Liquid Intramuscular; Intravenous Janssen Pharmaceutica, Division Of Janssen Ortho Inc. 1982-12-31 1996-09-10 Canada flag
Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image
Fentanyl Citrate Fentanyl citrate(25 ug/1mL) Injection, solution Intravenous Cantrell Drug Company 2014-08-21 2017-12-06 US flag
Fentanyl Citrate Fentanyl citrate(5 ug / 1毫升) Injection, solution Intravenous Cantrell Drug Company 2013-11-22 Not applicable US flag
Fentanyl Citrate Fentanyl citrate(50 ug/1mL) Injection, solution Intravenous Cantrell Drug Company 2011-10-20 Not applicable US flag
Fentanyl Citrate Fentanyl citrate(10 ug/1mL) Injection, solution Epidural; Intravenous Cantrell Drug Company 2013-04-23 2017-12-06 US flag
Fentanyl Citrate Fentanyl citrate(50 ug/1mL) Injection, solution Intravenous Cantrell Drug Company 2013-10-11 2017-12-06 US flag
Fentanyl Citrate Fentanyl citrate(20 ug/1mL) Injection, solution Intravenous Cantrell Drug Company 2014-08-13 Not applicable US flag
Fentanyl Citrate, Bupivacaine HCl Fentanyl citrate(1 ug/1mL)+Bupivacaine hydrochloride(1.25 mg/1mL) Injection, solution Epidural Cantrell Drug Company 2013-08-12 Not applicable US flag
Fentanyl Citrate, Bupivacaine HCl Fentanyl citrate(2 ug/1mL)+Bupivacaine hydrochloride(1 mg/1mL) Injection, solution Epidural Cantrell Drug Company 2013-09-09 2017-12-06 US flag
Fentanyl Citrate, Bupivacaine HCl Fentanyl citrate(3 ug/1mL)+Bupivacaine hydrochloride(1.25 mg/1mL) Injection, solution Epidural Cantrell Drug Company 2013-12-18 Not applicable US flag
Fentanyl Citrate, Bupivacaine HCl Fentanyl citrate(2 ug/1mL)+Bupivacaine hydrochloride(1.25 mg/1mL) Injection, solution Epidural Cantrell Drug Company 2013-03-25 Not applicable US flag

Categories

ATC Codes
N01AH01 — Fentanyl N02AB03 — Fentanyl N01AH51 — Fentanyl, combinations
Drug Categories
Chemical TaxonomyProvided byClassyfire
Description
This compound belongs to the class of organic compounds known as fentanyls. These are compounds containing the fentanyl moiety or a derivative, which is based on a N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylpropanamide skeleton.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Piperidines
Sub Class
Fentanyls
Direct Parent
Fentanyls
Alternative Parents
Phenethylamines/Anilides/Aralkylamines/Tertiary carboxylic acid amides/Trialkylamines/Amino acids and derivatives/Azacyclic compounds/Organopnictogen compounds/Organic oxides/Hydrocarbon derivatives
show 1 more
Substituents
Amine/Amino acid or derivatives/Anilide/Aralkylamine/Aromatic heteromonocyclic compound/Azacycle/Benzenoid/Carbonyl group/Carboxamide group/Carboxylic acid derivative
show 13 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
piperidines, monocarboxylic acid amide, anilide (CHEBI:119915)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
UF599785JZ
CAS number
437-38-7
InChI Key
PJMPHNIQZUBGLI-UHFFFAOYSA-N
InChI
InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3
IUPAC Name
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
SMILES
CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1

References

Synthesis Reference

Mark Rubino, "Process of making fentanyl intermediates." U.S. Patent US20060100438, issued May 11, 2006.

 US20060100438
一般References
  1. Van Bever WF, Niemegeers CJ, Janssen PA: Synthetic analgesics. Synthesis and pharmacology of the diastereoisomers of N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide and N-(3-methyl-1-(1-methyl-2-phenylethyl)-4-piperidyl)-N-phenylpropanamide. J Med Chem. 1974 Oct;17(10):1047-51. [Article]
  2. Taylor DR: Fentanyl buccal tablet: rapid relief from breakthrough pain. Expert Opin Pharmacother. 2007 Dec;8(17):3043-51. [Article]
  3. Simpson DM, Messina J, Xie F, Hale M: Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2007 Apr;29(4):588-601. [Article]
  4. Roy SD, Flynn GL: Solubility behavior of narcotic analgesics in aqueous media: solubilities and dissociation constants of morphine, fentanyl, and sufentanil. Pharm Res. 1989 Feb;6(2):147-51. [Article]
  5. DePriest AZ, Puet BL, Holt AC, Roberts A, Cone EJ: Metabolism and Disposition of Prescription Opioids: A Review. Forensic Sci Rev. 2015 Jul;27(2):115-45. [Article]
  6. Al-Hasani R, Bruchas MR: Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology. 2011 Dec;115(6):1363-81. doi: 10.1097/ALN.0b013e318238bba6. [Article]
  7. Bista SR, Haywood A, Hardy J, Lobb M, Tapuni A, Norris R: Protein binding of fentanyl and its metabolite nor-fentanyl in human plasma, albumin and alpha-1 acid glycoprotein. Xenobiotica. 2015 Mar;45(3):207-12. doi: 10.3109/00498254.2014.971093. Epub 2014 Oct 14. [Article]
  8. Raffa RB, Pergolizzi JV Jr, LeQuang JA, Taylor R Jr, Colucci S, Annabi MH: The fentanyl family: A distinguished medical history tainted by abuse. J Clin Pharm Ther. 2018 Feb;43(1):154-158. doi: 10.1111/jcpt.12640. Epub 2017 Oct 4. [Article]
  9. Schaefer CP, Tome ME, Davis TP: The opioid epidemic: a central role for the blood brain barrier in opioid analgesia and abuse. Fluids Barriers CNS. 2017 Nov 29;14(1):32. doi: 10.1186/s12987-017-0080-3. [Article]
  10. Cooper J, Jauniaux E, Gulbis B, Quick D, Bromley L: Placental transfer of fentanyl in early human pregnancy and its detection in fetal brain. Br J Anaesth. 1999 Jun;82(6):929-31. doi: 10.1093/bja/82.6.929. [Article]
  11. Streisand JB, Busch MA, Egan TD, Smith BG, Gay M, Pace NL: Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology. 1998 Feb;88(2):305-9. [Article]
  12. Parikh N, Goskonda V, Chavan A, Dillaha L: Pharmacokinetics and dose proportionality of fentanyl sublingual spray: a single-dose 5-way crossover study. Clin Drug Investig. 2013 Jun;33(6):391-400. doi: 10.1007/s40261-013-0079-8. [Article]
  13. Ashburn MA, Ogden LL, Zhang J, Love G, Basta SV: The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat. J Pain. 2003 Aug;4(6):291-7. [Article]
  14. Nave R, Schmitt H, Popper L: Faster absorption and higher systemic bioavailability of intranasal fentanyl spray compared to oral transmucosal fentanyl citrate in healthy subjects. Drug Deliv. 2013 Jun-Jul;20(5):216-23. doi: 10.3109/10717544.2012.762435. Epub 2013 May 8. [Article]
  15. FDA批准的药物连续cts: Abstral Sublingual Tablet [Link]
  16. FDA批准的药物连续cts: Actiq Transmucosal Lozenge [Link]
  17. FDA批准的药物连续cts: Fentora Buccal Tablet [Link]
  18. FDA批准的药物连续cts: Subsys Sublingual Spray [Link]
  19. FDA批准的药物连续cts: Duragesic Transdermal System [Link]
  20. FDA批准的药物连续cts: Lazanda Metered Nasal Spray [Link]
  21. FDA批准的药物连续cts: Sublimaze Preservative Free Intramuscular and Intravenous Injection [Link]
  22. CDC Drug Overdose Deaths 2017 [Link]
  23. Government of Canada: Canada's opioid crisis [Link]
Human Metabolome Database
HMDB0014951
KEGG Drug
D00320
PubChem Compound
3345
PubChem Substance
46506372
ChemSpider
3228
BindingDB
50008984
RxNav
4337
ChEBI
119915
ChEMBL
CHEMBL596
ZINC
ZINC000002522669
Therapeutic Targets Database
DAP000072
PharmGKB
PA449599
Guide to Pharmacology
GtP Drug Page
PDBe Ligand
7V7
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Fentanyl
PDB Entries
5tzo/8ef5
FDA label
Download (203 KB)
MSDS
Download (75.5 KB)

Clinical Trials

Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
4 Active Not Recruiting Treatment Acute Pain/Coronary Artery Disease (CAD)/Postoperative pain/Valvular Heart Disease 1
4 Active Not Recruiting Treatment Immunosuppression/Neoplasms, Lung/Pain 1
4 Active Not Recruiting Treatment Oocyte Retrieval/Postoperative pain 1
4 Completed Not Available Back Pain Lower Back 1
4 Completed Not Available Digestive System Diseases/Disorientation 1
4 Completed Not Available Failed Moderate Sedation During Procedure 1
4 Completed Not Available Haemorrhoids/Peri-anal Fistulas 1
4 Completed Basic Science Analgesic Drugs/Antinociceptive Agents 1
4 Completed Diagnostic Arrhythmia/Local Anaesthesia therapy/Renal Cancer/Surgery 1
4 Completed Diagnostic Pain 1

Pharmacoeconomics

Manufacturers
  • Ortho mcneil janssen pharmaceuticals inc
  • Actavis southatlantic llc
  • Lavipharm laboratories inc
  • Mylan technologies inc
  • Noven pharmaceuticals inc
  • Teva pharmaceuticals usa
  • Watson laboratories inc
  • Meda pharmaceuticals inc
  • Abbott laboratories hosp products div
  • Hospira inc
  • Baxter healthcare corp anesthesia and critical care
  • Marsam pharmaceuticals llc
  • Akorn inc
  • Cephalon inc
  • Barr laboratories inc
  • Mallinckrodt inc
  • Incline therapeutics inc
  • Abbott laboratories
Packagers
  • 4uOrtho LLC
  • Actavis Group
  • Akorn Inc.
  • Alza Corp.
  • Anesta Corp.
  • Apotex Inc.
  • Aveva Drug Delivery Systems Inc.
  • B&B Pharmaceuticals
  • Barr Pharmaceuticals
  • Baxter International Inc.
  • Cephalon Inc.
  • Chattem Chemicals Inc.
  • Cima Laboratories Inc.
  • Corium International Inc.
  • DAVA Pharmaceuticals
  • Dispensing Solutions
  • Hospira Inc.
  • Janssen-Ortho Inc.
  • LTS Lohmann Therapy Systems Corp.
  • Mallinckrodt Inc.
  • Meda AB
  • Medisca Inc.
  • Mylan
  • Nucare Pharmaceuticals Inc.
  • Ortho Mcneil Janssen Pharmaceutical Inc.
  • Pharmakon
  • Pharmedium
  • Physicians Total Care Inc.
  • Quality Care
  • Sandoz
  • Stat Rx Usa
  • Taylor Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Watson Pharmaceuticals
Dosage Forms
Form Route Strength
Tablet Sublingual 100 mcg
Tablet Sublingual 100 ug/1
Tablet Sublingual 200 mcg
Tablet Sublingual 200 ug/1
Tablet Sublingual 300 mcg
Tablet Sublingual 300 ug/1
Tablet Sublingual 400 mcg
Tablet Sublingual 400 ug/1
Tablet Sublingual 600 ug/1
Tablet Sublingual 600 mcg
Tablet Sublingual 800 mcg
Tablet Sublingual 800 ug/1
Tablet Sublingual
Tablet, orally disintegrating Sublingual 100 ug/1
Tablet, orally disintegrating Sublingual 200 ug/1
Tablet, orally disintegrating Sublingual 300 ug/1
Tablet, orally disintegrating Sublingual 400 ug/1
Tablet, orally disintegrating Sublingual 600 ug/1
Tablet, orally disintegrating Sublingual 800 ug/1
Lozenge Transmucosal 1200微克
Lozenge Transmucosal 1600 mcg
Lozenge Transmucosal 200 mcg
Lozenge Transmucosal 400 mcg
Lozenge Transmucosal 600 mcg
Lozenge Transmucosal 800 mcg
Lozenge Oral
Film Buccal
Injection Intramuscular; Intravenous 0.5 mg
Injection Parenteral 0.5 mg
Solution Intrasinal; Respiratory (inhalation) 100 mcg
Tablet
Patch, extended release Transdermal 12.5 ug/1h
Patch Transdermal 100 ug/1
Patch Transdermal 12.5 ug/1
Patch Transdermal 25 ug/1
Patch Transdermal 50 ug/1
Patch Transdermal 75 ug/1
Patch Transdermal 100 MCG
Patch Transdermal 12 MCG
Patch Transdermal 25 MCG
Patch Transdermal 50 MCG
Patch Transdermal 75 MCG
Patch Transdermal 5.5 mg
Patch Transdermal 11 mg
Patch Transdermal 1.375 mg
Patch Transdermal 2.75 mg
Patch Transdermal 8.25 mg
Patch Transdermal 2.1 mg
Patch Transdermal 100 μg/h
Plaster Transdermal
Patch Transdermal 16.8 mg
Patch Transdermal 12 μg/h
Patch Transdermal 25 μg/h
Patch, extended release Transdermal
Patch Transdermal 50 μg/h
Patch Transdermal 75 μg/h
Plaster Cutaneous 16.8 mg/1
Plaster Cutaneous 16.8 MG
Plaster Cutaneous 100 UG
Plaster Cutaneous 2.1 MG
Plaster Cutaneous 12 UG
Plaster Cutaneous 4.2 MG
Plaster Cutaneous 4.2 mg/1
Plaster Cutaneous 25 UG
Plaster Cutaneous 8.4 MG
Plaster Cutaneous 50 UG
Plaster Cutaneous 12.6 MG
Plaster Cutaneous 75 UG
Plaster Cutaneous 12.6 mg/1
Patch Transdermal 4.2 mg
Patch Transdermal 8.4 mg
Patch Transdermal 12.6 mg
Drug delivery system Transdermal 4.2 mg
Tablet Buccal 100 micrograms
Tablet Buccal 200 micrograms
Tablet Buccal 400 micrograms
Tablet Buccal 600 micrograms
Tablet Buccal 800 micrograms
Tablet Oral; Transmucosal 100 MCG
Tablet Oral; Transmucosal 200 MCG
Tablet Oral; Transmucosal 400 MCG
Tablet Oral; Transmucosal 600 MCG
Tablet Oral; Transmucosal 800 MCG
Tablet Buccal 100 mcg
Tablet Buccal 200 mcg
Tablet Buccal 400 mcg
Tablet Buccal 800 mcg
Patch Transdermal 2.89 mg
Patch Transdermal 5.78 mg/10.5sq cm
Patch Transdermal 11.56 mg/21sq cm
Solution Intramuscular; Intravenous 0.5 mg
Tablet Buccal
Plaster Cutaneous 37.5 UG
Injection, solution Intramuscular; Intravenous 0.1 mg/2mL
Injection, solution Parenteral 0.1 MG/2ML
Tablet Oral 100 MICROGRAMMI
Tablet Oral 200 MICROGRAMMI
Tablet Oral 400 MICROGRAMMI
Tablet Oral 600 MICROGRAMMI
Tablet Oral 800 MICROGRAMMI
Tablet Oral; Transmucosal 1200 MICROGRAMMI
Tablet Oral; Transmucosal 1600 MICROGRAMMI
Tablet Oral; Transmucosal 200 MICROGRAMMI
Tablet Oral; Transmucosal 400 MICROGRAMMI
Tablet Oral; Transmucosal 600 MICROGRAMMI
Tablet Oral; Transmucosal 800 MICROGRAMMI
Solution Intravenous 0.5 mg
Injection Intravenous 0.5 mg
Solution Intravenous 500 cg
Solution Intravenous 0.1 mg
Solution Intravenous 50 mcg
Injection
Patch Transdermal 1.28 mg/1[USP'U]
Patch Transdermal 10.20 mg/1[USP'U]
Patch Transdermal 12 ug/1
Patch Transdermal 12 ug/1h
Patch Transdermal 12.5 ug/1h
Patch Transdermal 2.55 mg/1[USP'U]
Patch Transdermal 37.5 ug/1h
Patch Transdermal 5.10 mg/1[USP'U]
Patch Transdermal 62.5 ug/1h
Patch Transdermal 7.65 mg/1[USP'U]
Patch Transdermal 87.5 ug/1h
Patch, extended release Transdermal 100 ug/1h
Patch, extended release Transdermal 12 ug/1h
Patch, extended release Transdermal 2.5 mg/72h
Patch, extended release Transdermal 25 ug/1h
Patch, extended release Transdermal 37.5 ug/1h
Patch, extended release Transdermal 5.0 mg/72h
Patch, extended release Transdermal 62.5 ug/1h
Patch, extended release Transdermal 7.5 mg/72h
Patch, extended release Transdermal 75 ug/1h
Patch, extended release Transdermal 87.5 ug/1h
Solution Parenteral 0.1 mg
Solution Intramuscular; Intravenous 0.1 mg/2ml
Solution Intramuscular; Intravenous 0.5 mg/10ml
Solution Intravenous 0.05 mg/ml
Plaster Cutaneous 150 UG
Patch Transdermal
Injection Intramuscular; Intravenous 50 mcg/ml
Solution Intravenous 0.785 mg
Tablet Buccal; Oral; Transmucosal 100 ug/1
Tablet Buccal; Oral; Transmucosal 200 ug/1
Tablet Buccal; Oral; Transmucosal 400 ug/1
Tablet Buccal; Oral; Transmucosal 600 ug/1
Tablet Buccal; Oral; Transmucosal 800 ug/1
Tablet Buccal; Sublingual 100 ug/1
Tablet Buccal; Sublingual 200 ug/1
Tablet Buccal; Sublingual 400 ug/1
Tablet Buccal; Sublingual 600 ug/1
Tablet Buccal; Sublingual 800 ug/1
Injection Intramuscular; Intravenous 50 ug/1mL
Injection Intravenous 50 ug/1mL
Injection, solution Epidural; Intravenous 10 ug/1mL
Injection, solution Intramuscular; Intravenous 0.05 mg/1mL
Injection, solution Intramuscular; Intravenous 100 ug/2mL
Injection, solution Intravenous 20 ug/1mL
Injection, solution Intravenous 25 ug/1mL
Injection, solution Intravenous 5 ug/1mL
Injection, solution Intravenous 50 ug/1mL
Lozenge Oral; Transmucosal 1200 ug/1
Lozenge Oral; Transmucosal 1600 ug/1
Lozenge Oral; Transmucosal 200 ug/1
Lozenge Oral; Transmucosal 800 ug/1
Lozenge Transmucosal 1200 ug/1
Lozenge Transmucosal 1600 ug/1
Lozenge Transmucosal 200 ug/1
Lozenge Transmucosal 400 ug/1
Lozenge Transmucosal 600 ug/1
Lozenge Transmucosal 800 ug/1
Injection Intramuscular; Intravenous 100 mcg/2ml
Solution Epidural; Intramuscular; Intravenous 50 mcg / mL
Injection, solution Epidural
Injection, solution Intramuscular; Intravenous 50 mcg/ml
Injection, solution Intravenous; Parenteral 50 MCG/ML
Injection, solution Parenteral 50 MICROGRAMMI/ML
Injection Intramuscular; Intravenous 0.1 mg/2ml
Solution Epidural; Intramuscular; Intravenous 100 mcg / 2 mL
Solution Epidural; Intramuscular; Intravenous 1000 mcg / 20 mL
Solution Epidural; Intramuscular; Intravenous 250 mcg / 5 mL
Solution Epidural; Intramuscular; Intravenous 2500 mcg / 50 mL
Solution 0.05 mg/mL
Injection, solution Parenteral
Injection, solution Intramuscular; Intravenous; Intravenous bolus 0.05 mg/ml
Injection, solution Intravenous 500 mg/10ml
Patch Transdermal 100 ug/1h
Patch Transdermal 25 ug/1h
Patch Transdermal 50 ug/1h
Patch Transdermal 75 ug/1h
Patch, extended release Transdermal 50 ug/1h
Patch, extended release Transdermal 100 mcg / hour
Patch, extended release Transdermal 25 mcg / hour
Patch, extended release Transdermal 50微克/小时
Patch, extended release Transdermal 75 mcg / hour
Injection, solution Intravenous 0.05 mg/ml
Injection, solution Intravenous
Plaster Cutaneous 100 MIKROGRAMM
Plaster Cutaneous 12 MIKROGRAMM
Plaster Cutaneous 25 MIKROGRAMM
Plaster Cutaneous 50 MIKROGRAMM
Plaster Cutaneous 75 MIKROGRAMM
Injection, solution Intramuscular; Intravenous 0.5 mg/10ml
Tablet Buccal; Oral; Transmucosal 300 ug/1
Tablet, effervescent Buccal; Sublingual 100 mcg
Tablet, effervescent Buccal; Sublingual 200 mcg
Tablet, effervescent Buccal; Sublingual 400 mcg
Tablet, effervescent Buccal; Sublingual 600 mcg
Tablet, effervescent Buccal; Sublingual 800 mcg
Tablet, effervescent Buccal 100 mcg
Tablet, effervescent Buccal 200 mcg
Tablet, effervescent Buccal 400 mcg
Tablet, effervescent Buccal 600 mcg
Tablet, effervescent Buccal 800 mcg
Patch Transdermal 14.4 mg
Liquid Intramuscular; Intravenous
Solution Nasal 100 mcg / dose
Solution Nasal 200 mcg / dose
Solution Nasal 50 mcg / dose
Spray Nasal 100 MCG
Spray Nasal 2 mg/1mL
Spray Nasal 200 MCG
Spray Nasal 50 MCG
Patch Transdermal 40 ?g/dose
Patch Transdermal 40 μg/dose
Patch Transdermal 40 ug/1
Patch, extended release, electrically controlled Transdermal 40 ug/10min
Solution Parenteral 250 mcg
Spray Nasal 100 ug/1
Spray Nasal 300 ug/1
Spray Nasal 400 ug/1
Injection, solution Intramuscular; Intravenous 50 MCG
Film, soluble Buccal 1200 ug/1
Film, soluble Buccal 1200微克
Film, soluble Buccal 200 mcg
Film, soluble Buccal 200 ug/1
Film, soluble Buccal 400 mcg
Film, soluble Buccal 400 ug/1
Film, soluble Buccal 600 ug/1
Film, soluble Buccal 600 mcg
Film, soluble Buccal 800 ug/1
Film, soluble Buccal 800 mcg
Patch Transdermal 12.0 mcg / hour
Spray Nasal 400 MCG
Spray, metered Nasal 100 mcg
Spray, metered Nasal 400 mcg
Injection Intramuscular; Intravenous
Patch Transdermal 10 mg
Patch Transdermal 2.5 mg
Patch Transdermal 5 mg
Patch Transdermal 7.5 mg
Patch Transdermal 37 mcg / hour
Injection, solution Intramuscular; Intravenous 50 ug/1mL
Liquid Epidural; Intramuscular; Intravenous 50 mcg / mL
Spray Sublingual 0.1 mg/1
Spray Sublingual 0.2 mg/1
Spray Sublingual 0.4 mg/1
Spray Sublingual 0.6毫克/1
Spray Sublingual 0.8 mg/1
Injection, solution Intramuscular; Intravenous
Injection, solution 0.1 mg/2ml
Injection, solution 0.5 mg/10ml
Patch Transdermal 100 mcg / hour
Patch Transdermal 12 mcg / hour
Patch Transdermal 25 mcg / hour
Patch Transdermal 50微克/小时
Patch Transdermal 75 mcg / hour
Lozenge Oral; Transmucosal 1200 1/1
Lozenge Oral; Transmucosal 400 ug/1
Lozenge Oral; Transmucosal 600 ug/1
Injection Parenteral
Tablet Sublingual 133 MICROGRAMMI
Tablet Sublingual 267 MICROGRAMMI
Tablet Sublingual 400 MICROGRAMMI
Tablet Sublingual 533 MICROGRAMMI
Tablet Sublingual 67年MICROGRAMMI
Tablet Sublingual 800 MICROGRAMMI
Tablet, orally disintegrating Sublingual
Prices
Unit description Cost Unit
芬太尼基粉 1498.18USD g
Fentanyl citrate powder 1062.5USD g
Duragesic-100 5 100 mcg/hr Patches Box 411.59USD box
Duragesic-75 5 75 mcg/hr Patches Box 318.93USD box
Fentanyl 5 100 mcg/hr Patches Box 210.0USD box
Duragesic-50 5 50 mcg/hr Patches Box 205.78USD box
Actiq 1600 mcg菱形 150.29USD lozenge
Fentanyl 5 50 mcg/hr Patches Box 129.99USD box
Actiq 1200 mcg lozenge 121.82USD lozenge
Actiq 1600 mcg Lollipop 119.42USD lollipop
Duragesic-25 5 25 mcg/hr Patches Box 114.42USD box
Duragesic-12 5 12 mcg/hr Patches Box 95.99USD box
Actiq 800 mcg lozenge 93.76USD lozenge
Actiq 1200 mcg Lollipop 85.7USD lollipop
Duragesic 100 mcg/hr patch 81.36USD patch
Actiq 600 mcg lozenge 79.16USD lozenge
Actiq 800 mcg Lollipop 75.98USD lollipop
Fentanyl 5 12 (12.5)mcg/hr Patches Box 67.99USD box
Fentanyl 5 25 mcg/hr Patches Box 66.66USD box
Actiq 600 mcg Lollipop 65.13USD lollipop
Actiq 400 mcg lozenge 64.62USD lozenge
Fentanyl 100 mcg/hr patch 61.69USD patch
Duragesic 75 mcg/hr patch 61.3USD patch
Fentora 800 mcg buccal tablet 54.77USD tablet
Actiq 400 mcg Lollipop 53.75USD lollipop
Actiq 200 mcg lozenge 51.05USD lozenge
含片Fentora 600微克 47.37USD tablet
Fentanyl 75 mcg/hr patch 46.48USD patch
Actiq 200 mcg Lollipop 42.14USD lollipop
Duragesic 50 mcg/hr patch 40.19USD patch
FentaNYL Citrate 1600 mcg Lollipop 38.53USD lollipop
Fentora 400 mcg buccal tablet 34.24USD tablet
Fentanyl 50 mcg/hr patch 30.47USD patch
FentaNYL Citrate 1200 mcg Lollipop 30.0USD lollipop
Fentora 300 mcg buccal tablet 28.84美元 tablet
Fentora 200 mcg buccal tablet 23.57USD tablet
Duragesic 25 mcg/hr patch 21.98USD patch
FentaNYL Citrate 400 mcg Lollipop 20.0USD lollipop
Fentora 100 mcg buccal tablet 18.64USD tablet
Duragesic 12 mcg/hr patch 18.21USD patch
Fentanyl 25 mcg/hr patch 16.67USD patch
Fentanyl 12 mcg/hr patch 13.8USD patch
Fentanyl 0.05 mg/ml vial 1.96USD ml
Fentanyl cit 1500 mcg/30 ml 1.44USD ml
Fentanyl-ns 50 mcg/ml syringe 1.0USD ml
Fentanyl-ns 300 mcg/30 ml syr 0.99USD ml
Fentanyl-ns 20 mcg/ml syringe 0.72USD ml
Fentanyl-ns 10 mcg/ml syringe 0.64USD ml
Fentanyl cit 2750 mcg/55 ml 0.35USD ml
Fentanyl-ns 500 mcg/50 ml syr 0.31USD ml
Sublimaze 0.05 mg/ml ampul 0.23USD ml
Fentanyl 0.05 mg/ml ampul 0.21USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region
US6317629 No 2001-11-13 2012-06-02 US flag
US6200604 No 2001-03-13 2019-03-26 US flag
US6974590 No 2005-12-13 2019-03-26 US flag
US8728441 No 2014-05-20 2019-03-26 US flag
US8753611 No 2014-06-17 2019-03-26 US flag
US8765100 No 2014-07-01 2019-03-26 US flag
US7862833 No 2011-01-04 2028-06-15 US flag
US8119158 No 2012-02-21 2024-12-30 US flag
US8092832 No 2012-01-10 2024-12-30 US flag
US7862832 No 2011-01-04 2028-06-15 US flag
US6761910 No 2004-07-13 2019-09-24 US flag
US6195582 No 2001-02-27 2019-01-28 US flag
US6881208 No 2005-04-19 2022-04-19 US flag
US8428709 No 2013-04-23 2032-06-11 US flag
US8428708 No 2013-04-23 2032-05-21 US flag
US6169920 No 2001-01-02 2018-01-02 US flag
US8781571 No 2014-07-15 2032-03-31 US flag
US6181963 No 2001-01-30 2019-11-02 US flag
US5843014 No 1998-12-01 2015-12-01 US flag
US5697896 No 1997-12-16 2016-12-16 US flag
US6975902 No 2005-12-13 2024-04-01 US flag
US8301238 No 2012-10-30 2031-09-30 US flag
US9095706 No 2015-08-04 2033-02-03 US flag
US7579019 No 2009-08-25 2020-01-22 US flag
US6159498 No 2000-12-12 2016-10-18 US flag
US6759059 No 2004-07-06 2019-09-24 US flag
US7910132 No 2011-03-22 2019-09-24 US flag
US8889176 No 2014-11-18 2024-01-16 US flag
US6432440 No 2002-08-13 2018-04-20 US flag
US8216604 No 2012-07-10 2024-10-03 US flag
US9078814 No 2015-07-14 2024-01-08 US flag
US8486973 No 2013-07-16 2030-04-27 US flag
US8835460 No 2014-09-16 2027-01-25 US flag
US8835459 No 2014-09-16 2027-01-25 US flag
US9241935 No 2016-01-26 2027-01-25 US flag
US8486972 No 2013-07-16 2030-04-27 US flag
US9364656 No 2016-06-14 2031-09-30 US flag
US9597288 No 2017-03-21 2027-07-23 US flag
US9642844 No 2017-05-09 2027-01-25 US flag
US9289387 No 2016-03-22 2027-01-25 US flag
US9642797 No 2017-05-09 2027-01-25 US flag
US9731869 No 2017-08-15 2032-01-26 US flag
US9731121 No 2017-08-15 2031-10-17 US flag
US9814705 No 2017-11-14 2024-01-08 US flag
US10016403 No 2018-07-10 2027-01-25 US flag
US10610523 No 2020-04-07 2027-01-25 US flag

Properties

State
Solid
Experimental Properties
Property Value Source
melting point (°C) 83-84 US. Patent 3,141,823.
water solubility 0.74mg/mL https://www.ncbi.nlm.nih.gov/pubmed/2569731
logP 4.05 SANGSTER (1993)
pKa 8.99 https://www.ncbi.nlm.nih.gov/pubmed/2569731
预测性能
Property Value Source
Water Solubility 0.024 mg/mL ALOGPS
logP 4.12 ALOGPS
logP 3.82 Chemaxon
logS -4.2 ALOGPS
pKa (Strongest Basic) 8.77 Chemaxon
Physiological Charge 1 Chemaxon
Hydrogen Acceptor Count 2 Chemaxon
Hydrogen Donor Count 0 Chemaxon
Polar Surface Area 23.55 Å2 Chemaxon
Rotatable Bond Count 6 Chemaxon
Refractivity 103.48 m3·mol-1 Chemaxon
Polarizability 39.89 Å3 Chemaxon
Number of Rings 3 Chemaxon
Bioavailability 1 Chemaxon
Rule of Five Yes Chemaxon
Ghose Filter Yes Chemaxon
Veber's Rule Yes Chemaxon
MDDR-like Rule Yes Chemaxon
Predicted ADMET Features
Property Value Probability
Human Intestinal Absorption + 0.9766
Blood Brain Barrier + 0.9901
Caco-2 permeable + 0.6459
P-glycoprotein substrate Substrate 0.6082
P-glycoprotein inhibitor I Inhibitor 0.7161
P-glycoprotein inhibitor II Non-inhibitor 0.8371
Renal organic cation transporter Inhibitor 0.5824
CYP450 2C9 substrate Non-substrate 0.7879
CYP450 2D6 substrate Non-substrate 0.9117
CYP450 3A4 substrate Substrate 0.5856
CYP450 1A2 substrate Non-inhibitor 0.7715
CYP450 2C9 inhibitor Non-inhibitor 0.873
CYP450 2D6 inhibitor Non-inhibitor 0.6327
CYP450 2C19 inhibitor Non-inhibitor 0.5724
CYP450 3A4 inhibitor Non-inhibitor 0.8218
CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.7346
Ames test Non AMES toxic 0.8417
Carcinogenicity Non-carcinogens 0.8536
Biodegradation Not ready biodegradable 0.8554
Rat acute toxicity 3.9836 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.796
hERG inhibition (predictor II) Inhibitor 0.6791
ADMET data is predicted usingadmetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Spectrum Spectrum Type Splash Key
Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available
Mass Spectrum (Electron Ionization) MS splash10-0002-9850000000-7ce3a6f35f5dee98185f
Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positive LC-MS/MS splash10-000i-0009000000-62593b54c6285a566893
LC-MS/MS Spectrum - LC-ESI-QTOF , positive LC-MS/MS splash10-000i-0209000000-d550d803c25d31570227
LC-MS/MS Spectrum - LC-ESI-QTOF , positive LC-MS/MS splash10-000i-0901000000-09bd125eea134f8811a4
LC-MS/MS Spectrum - LC-ESI-QTOF , positive LC-MS/MS splash10-000i-0900000000-2c34993eade063cb426f
LC-MS/MS Spectrum - LC-ESI-QTOF , positive LC-MS/MS splash10-001r-0900000000-beb72ea99dc9c125d29b
LC-MS/MS Spectrum - LC-ESI-QFT , positive LC-MS/MS splash10-000i-0009000000-bf70e4d857c26d30032f
LC-MS/MS Spectrum - LC-ESI-QFT , positive LC-MS/MS splash10-000i-0907000000-a9f5d0c422eff1474d38
LC-MS/MS Spectrum - LC-ESI-QFT , positive LC-MS/MS splash10-000i-0900000000-0c03ba9ef576114a9503
LC-MS/MS Spectrum - LC-ESI-QFT , positive LC-MS/MS splash10-0a4i-0900000000-d2a36b402c3a7424fab6
LC-MS/MS Spectrum - LC-ESI-QFT , positive LC-MS/MS splash10-0a4i-1900000000-e0cbdfad80c306baabc1
LC-MS/MS Spectrum - LC-ESI-QFT , positive LC-MS/MS splash10-0a4i-2900000000-ea551550ac6cbe6d3960
LC-MS/MS Spectrum - LC-ESI-QFT , positive LC-MS/MS splash10-0pdi-8900000000-89b1a77e558ec74cf3ac
LC-MS/MS Spectrum - LC-ESI-QFT , positive LC-MS/MS splash10-0kdj-9400000000-358833c028a079789d0b
LC-MS/MS Spectrum - LC-ESI-QFT , positive LC-MS/MS splash10-0ufs-9200000000-ff2c211a084a5f124781

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets tounlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details 1.Mu-type opioid receptor
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
一般Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
分子量
44778.855 Da
References
  1. You HJ, Colpaert FC, Arendt-Nielsen L: The novel analgesic and high-efficacy 5-HT1A receptor agonist F 13640 inhibits nociceptive responses, wind-up, and after-discharges in spinal neurons and withdrawal reflexes. Exp Neurol. 2005 Jan;191(1):174-83. [Article]
  2. Scott LJ, Perry CM: Remifentanil: a review of its use during the induction and maintenance of general anaesthesia. Drugs. 2005;65(13):1793-823. [Article]
  3. Scott LJ, Perry CM: Spotlight on remifentanil for general anaesthesia. CNS Drugs. 2005;19(12):1069-74. [Article]
  4. Dosen-Micovic L, Ivanovic M, Micovic V: Steric interactions and the activity of fentanyl analogs at the mu-opioid receptor. Bioorg Med Chem. 2006 May 1;14(9):2887-95. Epub 2006 Jan 11. [Article]
  5. Dardonville C, Fernandez-Fernandez C, Gibbons SL, Ryan GJ, Jagerovic N, Gabilondo AM, Meana JJ, Callado LF: Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites. Bioorg Med Chem. 2006 Oct 1;14(19):6570-80. Epub 2006 Jun 23. [Article]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
  7. Hajiha M, DuBord MA, Liu H, Horner RL: Opioid receptor mechanisms at the hypoglossal motor pool and effects on tongue muscle activity in vivo. J Physiol. 2009 Jun 1;587(Pt 11):2677-92. doi: 10.1113/jphysiol.2009.171678. Epub 2009 Apr 29. [Article]
Details 2.Delta-type opioid receptor
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
一般Function
Opioid receptor activity
Specific Function
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name
OPRD1
Uniprot ID
P41143
Uniprot Name
Delta-type opioid receptor
分子量
40368.235 Da
References
  1. Rodrigues AR, Castro MS, Francischi JN, Perez AC, Duarte ID: Participation of ATP-sensitive K+ channels in the peripheral antinociceptive effect of fentanyl in rats. Braz J Med Biol Res. 2005 Jan;38(1):91-7. Epub 2005 Jan 18. [Article]
  2. Poonawala T, Levay-Young BK, Hebbel RP, Gupta K: Opioids heal ischemic wounds in the rat. Wound Repair Regen. 2005 Mar-Apr;13(2):165-74. [Article]
  3. Sahin AS, Duman A, Atalik EK, Ogun CO, Sahin TK, Erol A, Ozergin U: The mechanisms of the direct vascular effects of fentanyl on isolated human saphenous veins in vitro. J Cardiothorac Vasc Anesth. 2005 Apr;19(2):197-200. [Article]
  4. Darwish M, Tempero K, Kirby M, Thompson J: Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet. 2005;44(12):1279-86. [Article]
  5. Darwish M, Kirby M, Robertson P Jr, Tracewell W, Jiang JG: Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. Clin Ther. 2006 May;28(5):707-14. [Article]
  6. Hajiha M, DuBord MA, Liu H, Horner RL: Opioid receptor mechanisms at the hypoglossal motor pool and effects on tongue muscle activity in vivo. J Physiol. 2009 Jun 1;587(Pt 11):2677-92. doi: 10.1113/jphysiol.2009.171678. Epub 2009 Apr 29. [Article]
Details 3.Kappa-type opioid receptor
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Agonist
一般Function
Opioid receptor activity
Specific Function
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name
OPRK1
Uniprot ID
P41145
Uniprot Name
Kappa-type opioid receptor
分子量
42644.665 Da
References
  1. Pascoe JE, Williams KL, Mukhopadhyay P, Rice KC, Woods JH, Ko MC: Effects of mu, kappa, and delta opioid receptor agonists on the function of hypothalamic-pituitary-adrenal axis in monkeys. Psychoneuroendocrinology. 2008 May;33(4):478-86. doi: 10.1016/j.psyneuen.2008.01.006. Epub 2008 Mar 5. [Article]
Details 4.P-glycoprotein 1
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
一般Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
分子量
141477.255 Da
References
  1. Wandel C, Kim R, Wood M, Wood A: Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology. 2002 Apr;96(4):913-20. [Article]

Enzymes

Details 1.Cytochrome P450 3A4
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
一般Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
分子量
57342.67 Da
References
  1. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [Article]
  2. Feierman DE, Lasker JM: Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. Drug Metab Dispos. 1996 Sep;24(9):932-9. [Article]
  3. Flockhart Table of Drug Interactions [Link]
Details 2.Cytochrome P450 3A7
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
一般Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
分子量
57525.03 Da
References
  1. Flockhart Table of Drug Interactions [Link]

Carriers

Details 1.Serum albumin
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Binder
一般Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
分子量
69365.94 Da
References
  1. Bista SR, Haywood A, Hardy J, Lobb M, Tapuni A, Norris R: Protein binding of fentanyl and its metabolite nor-fentanyl in human plasma, albumin and alpha-1 acid glycoprotein. Xenobiotica. 2015 Mar;45(3):207-12. doi: 10.3109/00498254.2014.971093. Epub 2014 Oct 14. [Article]
Details 2.alpha1-acid gcoprotein (Protein Group)
Kind
Protein group
Organism
Humans
Pharmacological action
Unknown
Actions
Binder
一般Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Components:
Name UniProt ID
Alpha-1-acid glycoprotein 1 P02763
Alpha-1-acid glycoprotein 2 P19652
References
  1. Bista SR, Haywood A, Hardy J, Lobb M, Tapuni A, Norris R: Protein binding of fentanyl and its metabolite nor-fentanyl in human plasma, albumin and alpha-1 acid glycoprotein. Xenobiotica. 2015 Mar;45(3):207-12. doi: 10.3109/00498254.2014.971093. Epub 2014 Oct 14. [Article]

Transporters

Details 1.P-glycoprotein 1
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
一般Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
分子量
141477.255 Da
References
  1. Wandel C, Kim R, Wood M, Wood A: Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology. 2002 Apr;96(4):913-20. [Article]

Drug created at June 13, 2005 13:24 / Updated at February 02, 2023 04:04